Abstract
The past 10 years have seen major changes in the way we look at chronic obstructive pulmonary disease and how we manage it. At present, we still have yet to find a therapy that changes the prognosis or reverses disease progression [1], with smoking cessation being the only effective intervention to achieve this.
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
Keywords
- Chronic Obstructive Pulmonary Disease
- Smoking Cessation
- Fluticasone Propionate
- Pulmonary Rehabilitation
- Tiotropium Bromide
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005; 25:1084–1106.
van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26:214–222.
Tudorza Pressair [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2012.
European Medicines Agency. Summary of product characteristics for Eklira Genuair. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/ human/002211/WC500132661.pdf. Last accessed October 2012.
Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J 2009; 34:757-769.
Villetti G, Pastore F, Bergamaschi M, et al. Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl) [(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1- azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonist. J Pharmacol Exp Ther 2010; 335:622-635.
Cazzola M, Calzetta L, Matera MG. β2-adrenoreceptor agonists: current and future direction. Br J Pharmacol 2011; 163:4-17.
European Medicines Agency. Summary of product characteristics for Onbrez Breezhaler. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/001114/WC500053732.pdf. Last accessed October 2012.
Arcapta Neohaler [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011.
van Noord JA, Smeets JJ, Drenth BM, et al. 24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD. Pulm Pharmacol Ther 2011; 24:666-672.
Calverly PM, Anderson JA, Celli B, et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775–789.
The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. JAMA 2000; 283:3244–3254.
Gonzales D, Rennard SI, Nides M, et al; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296:47-55.
Jorenby DE, Hays JT, Rigotti NA, et al; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296:56-63.
Barnes PJ. Reduced histone deacetylase in COPD: clinical implications. Chest 2006; 129:151–155.
Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc 2005; 2:334–339.
Ford PA, Durham A, Russell RE, et al. Treatment effects of low dose theophylline combined with an inhaled corticosteroid in COPD. Chest 2010;137:1338–1344.
Cosio BG, Iglesias A, Rios A, et al. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax 2009; 64:424-429.
Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004; 364:985–996.
Sturton G, Persson C, Barnes PJ. Small airways: an important but neglected target in the treatment of obstructive airway diseases. Trends Pharmacol Sci 2008; 29:340-345.
Fan CK. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 2006; 533:110–117.
Barnes PJ. New therapies for chronic obstructive pulmonary disease. Med Princ Pract 2010; 19:330-338.
Barnes PJ. Frontrunners in novel pharmacotherapy of COPD. Curr Opin Pharmacol 2008; 8:300-307.
Daliresp [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2011.
Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharm Rev 2004; 56:515–548.
Leidy NK, Wilcox TK, Jones PW, et al; for the EXACT-PRO Study Group. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease (EXACT): a Patient Reported Outcome (PRO) measure. Value Health 2010; 13:965-975.
Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 2009; 180:1189-1195.
Thiberville L, Salaun M, Lachkar S, et al. Human in vivo fluorescence microimaging of the alveolar ducts and sacs during bronchoscopy. Eur Respir J 2009; 33:974-985.
van Noord JA, Cornelissen PJ, Aumann JL, et al. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med 2009; 103:22-29.
Asakura Y, Nishimura N, Maezawa K, et al. Effect of switching Tiotropium HandiHalerR to RespimatR Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices. J Aerosol Med Pulm Drug Deliv 2012; epub ahead of print.
Rosenberg SR, Kalhan R. An integrated approach to the medical treatment of chronic obstructive pulmonary disease. Med Clin North Am. 2012; 96:811-826.
Bach PB, Brown C, Gelfand SE, et al; American College of Physicians–American Society of Internal Medicine; American College of Chest Physicians. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001; 134:600–620.
Ferlay J, Shin H-R, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-2917.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Healthcare
About this chapter
Cite this chapter
Russell, R., Ford, P., Barnes, P.J., Russell, S. (2013). The Future of COPD. In: Managing COPD. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-52-8_6
Download citation
DOI: https://doi.org/10.1007/978-1-907673-52-8_6
Published:
Publisher Name: Springer Healthcare, Tarporley
Print ISBN: 978-1-908517-69-2
Online ISBN: 978-1-907673-52-8
eBook Packages: MedicineMedicine (R0)